Lite Strategy (LITS) AI Stock Analysis

• Market Cap: $91.95M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: -100.00%
• EPS Growth: -221.06%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 32,837,740
• 10 Day Avg. Volume: 2,594,476
• 30 Day Avg. Volume: 1,201,359
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

MEI Pharma's overall stock score is low, primarily due to significant financial performance challenges and poor valuation metrics. Weak revenue and profitability, declining asset base, and negative cash flow contribute to a fragile financial position. Additionally, technical indicators suggest a bearish trend, further impacting investor sentiment. Without clear guidance or positive corporate events, the stock's outlook remains unfavorable.

Lite Strategy Business Overview & Revenue Model

Company Description

A company that has pivoted from purely oncology / pharmaceutical development to also holding Litecoin (LTC) as its primary treasury reserve asset. The company is acquiring LTC, launching a digital asset treasury strategy, while maintaining its pipeline of drug development.

How the Company Makes Money

MEI Pharma makes money primarily through the development and commercialization of its oncology drug candidates. The company generates revenue from licensing agreements, milestone payments, and potential royalties related to the commercialization of its drug candidates. These agreements are often formed with larger pharmaceutical companies that have the resources to bring a drug to market. MEI Pharma's business strategy also involves strategic partnerships and collaborations that can provide funding and expertise for the continued development of its pipeline products. Additionally, the company may receive funding from government grants or research organizations to support its clinical trials and research activities.

Lite Strategy Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Lite Strategy Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Negative. The current price of 2.8 is below the 20-day moving average (MA) of 3.85, below the 50-day MA of 4.56, and below the 200-day MA of 2.94, indicating a bearish trend. The MACD of -0.55 indicates Positive momentum. The RSI at 32.12 is Neutral, neither overbought nor oversold. The STOCH value of 14.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LITS.

Lite Strategy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SABS	48 Neutral	25.72M	-0.62	-131.33%	―	-95.87%	35.25%
BOLT	44 Neutral	10.04M	-0.20	-110.35%	―	-62.68%	23.94%
PHIO	42 Neutral	11.85M	-0.62	0.00%	―	0.00%	85.26%
LITS	41 Neutral	$91.95M	―	-89.73%	―	-100.00%	-221.06%
COCP	40 Underperform	17.34M	-1.08	0.00%	―	0.00%	29.97%
INAB	34 Underperform	9.08M	-0.19	0.00%	―	0.00%	58.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%